Abstract

Oral anti vascular endothelial growth factors therapeutic agents have been evolving rapidly over the last past decades and became one of the great contributors to advancement of cancer therapy and increasing survival rate of the treated patients.

Sorafenib is FDA approved medications for the treatment of solid tumors.

In this article, we reported the clinical features of the first Saudi patient presenting with corneo-uveal retinal adverse effects with subsequent bilateral irreversible blindness.

Keywords: Hepatocellular Carcinoma; Targeted Anti-Cancer Therapy; Sorafenib; Oral Anti-Vascular Endothelial Growth Factor; Ocular Toxicity; Irreversible Blindness

References

1. Siegel RL., et al. “Cancer statistics, 2020”. CA: A Cancer Journal for Clinicians 1 (2020): 7-30.
2. Rehman FU., et al. “Anticancer therapeutics: a brief account on wide refinements”. American Journal of Cancer Research 11 (2020): 3599-3621.
3. Dembic Z. “Antitumor drugs and their targets”. Molecules (2020).
4. Dalvin LA., et al. “Checkpoint Inhibitor Immune Therapy: systemic indications and ophthalmic side effects”. Retina6 (2018): 1063-1078.
5. Fortes BH., et al. “Ophthalmic adverse effects of immune checkpoint inhibitors: The Mayo Clinic experience”. British Journal of Ophthalmology (2020).
6. Roberts PJ and Der CJ. “Targeting the Raf -MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer”. Oncogene 26 (2007): 3291-310.
7. King J., et al. “Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit”. Journal of Clinical Oncology 4 (2017): 256-262.
8. Imperia PS., et al. “Ocular complications of systemic cancer chemotherapy”. Survey of Ophthalmology 34 (1989): 209-230.
9. Fortes BH., et al. “Ocular Toxicity of Targeted Anticancer Agents”. Drugs (2021).
10. FT Fraunfelder. “FW Fraunfelder”. Journal of Ocular Pharmacology and Therapeutics (2018).
11. Harman LE. “Ophthalmic complications related to chemotherapy in medically complex patients”. Cancer Control 23 (2016): 150-156.
12. Wegner A and Khoramnia R. “Neurosensory retinal detachment due to sunitinib treatment”. Eye 25 (2011): 1517-1518.
13. Hasan R. “A retinal tear induced by pazopanib therapy: a case report”. Medical Education Forum 16 (2015): 1-3.
14. Gaertner KM., et al. “A case of retinal tear associated with use of sorafenib”. Frontiers in Oncology 4 (2014): 1-2.
15. Bhatia S., et al. “Phase II trial of sorafenib in combination with carboplastin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512”. PLoS ONE 11 (2012): e48787.
16. Li ZY., et al. “Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib”. Oncotarget 23 (2016): 35181-35187.
17. Szczepanik S and Kecik D. “Bilateral central retinal vein occlusion in a patient with disseminated metastatic renal cell carcinoma treated with sorafenib”. Retinal Cases and Brief Reports 2 (2012): 148-150.
18. Hussain SZ., et al. “Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib”. BMC Endocrine Disorders 13 (2013): 29.

Citation

Citation: Maaly Abdel Halim Abdel Fattah., et al. “Corneo-Uveal-Retinal Adverse Effects after Single Course of Targeted Anti-Cancer Therapy: Case Report and Review of Literature".Acta Scientific Ophthalmology 4.6 (2021): 69-75.

Copyright

Copyright: © 2021 Maaly Abdel Halim Abdel Fattah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.